Modulation of matrix metalloproteinase and cytokine production by licorice isolates licoricidin and licorisoflavan A: potential therapeutic approach for periodontitis

J Periodontol. 2011 Jan;82(1):122-8. doi: 10.1902/jop.2010.100342. Epub 2010 Aug 19.

Abstract

Background: Inflammatory cytokines and matrix metalloproteinases (MMPs) produced by resident and inflammatory cells in response to periodontopathogens play a major role in the tissue destruction observed in periodontitis, which is a disease that affects tooth-supporting structures. In the present study, we investigate the effects of licorice-derived licoricidin (LC) and licorisoflavan A (LIA) on the secretion of various cytokines and MMPs by human monocyte-derived macrophages stimulated with Aggregatibacter actinomycetemcomitans (previously Actinobacillus actinomycetemcomitans) lipopolysaccharide (LPS).

Methods: Macrophages were treated with non-toxic concentrations of LC or LIA before being stimulated with A. actinomycetemcomitans LPS. The secretion of cytokines and MMPs and the activation of nuclear factor-kappa B (NF-κB) p65 and activator protein (AP)-1 were assessed by enzyme-linked immunosorbent assays.

Results: LC and LIA inhibited the secretion of interleukin (IL)-6 and chemokine (C-C motif) ligand 5 in a concentration-dependent manner but did not affect the secretion of IL-8 by LPS-stimulated macrophages. LC and LIA also inhibited the secretion of MMP-7, -8, and -9 by macrophages. The suppression of cytokine and MMP secretion by LC and LIA was associated with the reduced activation of NF-κB p65 but not that of AP-1.

Conclusion: The present study suggests that LC and LIA have potential for the development of novel host-modulating strategies for the treatment of cytokine and/or MMP-mediated disorders such as periodontitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aggregatibacter actinomycetemcomitans
  • Benzopyrans / pharmacology*
  • Cell Line, Tumor
  • Chemokine CCL5 / antagonists & inhibitors
  • Cytokines / drug effects*
  • Enzyme Inhibitors / pharmacology
  • Flavonoids / pharmacology*
  • Glycyrrhiza*
  • Humans
  • Inflammation Mediators / immunology
  • Interleukin-6 Inhibitors
  • Interleukin-8 / drug effects
  • Lipopolysaccharides / pharmacology
  • Macrophages / drug effects*
  • Macrophages / enzymology
  • Macrophages / immunology
  • Matrix Metalloproteinase 7
  • Matrix Metalloproteinase 8
  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinases / drug effects*
  • Plant Extracts / pharmacology*
  • Transcription Factor AP-1 / drug effects
  • Transcription Factor RelA / drug effects

Substances

  • Benzopyrans
  • Chemokine CCL5
  • Cytokines
  • Enzyme Inhibitors
  • Flavonoids
  • Inflammation Mediators
  • Interleukin-8
  • Lipopolysaccharides
  • Matrix Metalloproteinase 7
  • Matrix Metalloproteinase 8
  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinases
  • Plant Extracts
  • Transcription Factor AP-1
  • Transcription Factor RelA
  • Interleukin-6 Inhibitors
  • licorisoflavan A
  • licoricidin
  • MMP7 protein, human
  • MMP8 protein, human